Spyre Therapeutics advances SPY003 as standalone and combination IBD treatment after $350M raise

Spyre Therapeutics is advancing SPY003, a long-acting IL-23 antibody for inflammatory bowel disease, as a standalone treatment and in combination regimens after raising $350 million, bringing total capital to over $2 billion.

Detected & updated continuously · Source: Nebula